Latest Channelopathy Stories
ATLANTA, June 2, 2015 /PRNewswire/ -- Celtaxsys, a clinical stage drug development company focused on advancing care for patients suffering from inflammatory diseases, including those with rare
For Rare Eye Disease First Appearing in Childhood or Adolescence LEXINGTON, Massachusetts and COLUMBIA, Maryland, May 4, 2015 /PRNewswire/ -- Shire plc (LSE: SHP,
Prime Therapeutics study finds combination treatment targeting gene mutations could add approximately $150 million per year in new costs ST.
Take A Breather Foundation Fulfills Wishes Exclusively for Children Living with Cystic Fibrosis (CF). Haverford, PA (PRWEB) March 17, 2015
As part of a limited panel, the nation's largest independent specialty pharmacy will offer PARI's cystic fibrosis treatment, a 28-day supply of Tobramycin Inhalation Solution together with a PARI LC
DALLAS, March 12, 2015 /PRNewswire/ -- RnRMarketResearch.com adds "Cystic Fibrosis - Pipeline Review, H1 2015" therapeutic market research report provides an overview of
BOULDER, Colo., Feb.
BOULDER, Colo., Feb. 3, 2015 /PRNewswire/ -- N30 Pharmaceuticals, Inc.
Global Cystic Fibrosis Market 2015-2019 is a new industry research report which profiles key players like Actavis, Novartis, Gilead Sciences, Vertex Pharmaceuticals and F Hoffmann-La Roche.
Cystic fibrosis, also called mucoviscidosis, is an autosomal recessive genetic disorder of the viscous secretions in the body. In turn, it effects the lungs, pancreas, liver, and intestines, as well as all other exocrine glands in the body. The most common genetic mutation that causes CF is a deletion of three nucleotides that results in a loss of phenylalanine, an amino acid at the 508th position on the protein. It should be noted, however, that there are over a thousand other mutations that...
- The parings of haberdine; also, any kind of fragments.